Oral Antibiotic Management of Non‑Purulent Cellulitis

First‑Line Oral Therapy for Typical Non‑Purulent Cellulitis

Cephalexin 500 mg orally four times daily for 5 days is recommended as the primary agent because β‑lactams effectively cover β‑hemolytic streptococci and methicillin‑susceptible Staphylococcus aureus without needing routine MRSA coverage. (Clinical Infectious Diseases, 2014) 1
Dicloxacillin 500 mg orally four times daily for 5 days is an equivalent first‑line option for the same reasons. (Clinical Infectious Diseases, 2014) 1
Amoxicillin (appropriate streptococcal dosing) and penicillin (for penicillin‑susceptible streptococci) are acceptable alternatives when β‑lactam choice is limited. (Clinical Infectious Diseases, 2014) 1

A 5‑day course is sufficient if clinical improvement (reduced erythema, swelling, tenderness) is evident by day 5; extending therapy provides no additional benefit. (Annals of Internal Medicine, 2021 – moderate‑quality evidence) 4

Prospective data show 96 % clinical success with β‑lactam regimens in non‑purulent cellulitis, confirming that routine MRSA coverage is unnecessary in typical cases. (Clinical Infectious Diseases, 2014) 1

Cephalexin remains appropriate unless the patient has a history of immediate (IgE‑mediated) hypersensitivity. (Clinical Infectious Diseases, 2005) 3
Clindamycin 300–450 mg orally three times daily is an alternative that provides coverage for both streptococci and MRSA. (Clinical Infectious Diseases, 2005) 3

Routine MRSA coverage is not indicated for non‑purulent cellulitis; it should be added only when any high‑risk feature is present. (Clinical Infectious Diseases, 2014) 1

Lack of clinical response after 48–72 hours of β‑lactam therapy.
Presence of purulent drainage or exudate (purulent phenotype).
Penetrating trauma (especially injection‑drug use).
Documented MRSA colonization elsewhere.
Systemic toxicity (fever, hypotension, altered mental status, or meeting SIRS criteria).

Clindamycin 300–450 mg orally three times daily – covers both pathogens. (Clinical Infectious Diseases, 2005) 3
Linezolid 600 mg orally twice daily – provides dual coverage but is more costly. (Clinical Infectious Diseases, 2005) 3

Trimethoprim‑sulfamethoxazole (1–2 double‑strength tablets) orally twice daily plus amoxicillin or cephalexin. (Clinical Infectious Diseases, 2014) 1
Doxycycline 100 mg orally twice daily plus a β‑lactam. (Clinical Infectious Diseases, 2005) 3
Minocycline 100 mg orally twice daily plus a β‑lactam. (Clinical Infectious Diseases, 2005) 3

Reassess at 48–72 hours to confirm improvement in erythema, swelling, and tenderness. (Praxis Medical Insights, 2026) 2
If no improvement by day 5, switch to an MRSA‑active regimen and consider imaging to exclude abscess or deeper infection. (Praxis Medical Insights, 2026) 2
Elevate the affected limb to facilitate edema drainage and accelerate clinical response. (Clinical Infectious Diseases, 2014) 1

Do not use TMP‑SMX or doxycycline as monotherapy for non‑purulent cellulitis; they lack reliable streptococcal activity and must be combined with a β‑lactam. (Clinical Infectious Diseases, 2014) 1
Avoid adjunctive rifampin; it provides no benefit and promotes resistance. (Clinical Infectious Diseases, 2014) 1
Do not extend therapy beyond 5 days in patients who are clinically improving; this constitutes overtreatment. (Annals of Internal Medicine, 2021) 4
Routine blood cultures or imaging are unnecessary for typical outpatient cellulitis; reserve them for severe systemic features, immunosuppression, or atypical exposures. (Praxis Medical Insights, 2026) 2
Use clindamycin only when local resistance rates are <10 % to avoid treatment failure. (World Journal of Emergency Surgery, 2018) 5

Pregnancy: Avoid TMP‑SMX in the third trimester and avoid all tetracyclines throughout pregnancy. (Praxis Medical Insights, 2026) 2
Children < 8 years: Avoid tetracyclines (including doxycycline and minocycline). (Clinical Infectious Diseases, 2005) 3
Elderly patients on ACE inhibitors or with renal insufficiency: TMP‑SMX increases the risk of hyperkalemia. (Praxis Medical Insights, 2026) 2

Address predisposing factors such as tinea pedis, lymphedema, and venous insufficiency, and optimize wound care to reduce recurrence risk. (Clinical Infectious Diseases, 2014) 1
For patients with recurrent cellulitis, consider prophylactic penicillin or erythromycin after underlying risk factors have been managed. (Clinical Infectious Diseases, 2014) 1